AML-432 Overall Survival (OS) by Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant- Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial

Courtney D. DiNardo, Maroof Hasan, Amir T. Fathi et al.|Clinical Lymphoma Myeloma & Leukemia|2022

Cited by 0